An observational study in Alzheimer's Disease, sponsored by Eisai Inc.. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Eisai Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Alzheimer Disease by Eisai Co., Ltd. — 7 open to participants now, 12 under way, 2 of them phase 3. Alzheimer Disease · Eisai Co., Ltd..
Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 10th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 41st registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →7 of the 46 studies in Alzheimer Disease by Eisai Co., Ltd. are open now, in 4 countries. Recruiting first, the newest first:
Eisai Limited · Sites in Canada
Eisai Inc. · Sites in United States
Eisai Korea Inc. · Sites in United States
Ages 19+
Eisai Co., Ltd. · Sites in Japan
Ages 18+
Eisai Limited · Sites in United Kingdom
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 8 · Phase 4 9
First in 2001; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 99 across the 30 interventional studies, 2,000 across the 15 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
2 of the studies in Alzheimer Disease by Eisai Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06602258Eisai Inc.A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | 2026-12-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to develop and validate claims-based algorithms to identify intracerebral hemorrhage >1 cm in diameter, ensuring differentiation from amyloid-related imaging abnormality-microhemorrhage and hemosiderin deposit (ARIA-H; microhemorrhage, superficial siderosis) in participants with Alzheimer's disease (AD) using claims data in the United States (US) with linkage to electronic health records (EHRs), and to estimate the positive predictive values (PPVs) of the algorithms. The secondary objective of the study is to validate claims-based algorithms to identify new-onset seizures in participants with AD using US claims data with linkage to EHRs and to estimate the PPVs of the algorithms.
As this is a Retrospective Database Study, the Study Start Date for this study references the date at which the first set of data will become available.
The study includes participants with at least one Alzheimer's disease diagnosis in claims data from January 2016 to July 2025 (or the latest available data).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: No intervention
This is a non-interventional study.
Positive Predictive Value (PPV) of algorithms to identify intracerebral hemorrhage >1 cm in diameter
Time frame: Up to 9.5 years
PPV of algorithms to identify new-onset seizure
Time frame: Up to 9.5 years
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2026 → Dec 2029 and completion Dec 2026 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.